|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only among AA women, IL15 rs10833 and IL15RA rs2296135 were associated with ER-positive tumors, and IL12RB1 rs375947, IL15 rs10833 and TGFB1 rs1800469 were associated with ER-negative tumors.
|
23996684 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To test whether the p53-impaired function that is frequently found in this tumour type could play a role in the IL-15 production, wild-type p53 gene was transduced in the human rhabdomyosarcoma cell line RD (which harbours a mutated p53 gene), and its effect on proliferation and expression of IL-15 was studied.
|
9862562 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall, the transient localized expression of IL-15 in the tumour by an oncolytic virus was able to induce stronger anti-tumoral immunity in a murine model of colon carcinoma.
|
22158521 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data strongly indicated that tumor vaccine modified with NDV strain LX/IL(15+7) is a promising agent for cancer immunotherapy.
|
29224228 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, these results indicate that expression of IL-15 in the tumor microenvironment may prevent the escape of antigen loss variants and subsequent tumor recurrence by enabling T cells to eliminate cancer cells lacking cognate antigen expression in a locally restricted manner.
|
23637340 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
N592 cells engineered with IL-2 (N592/IL-2) were promptly rejected, while N592/IL-15 displayed a significant delay in tumour growth and a slightly reduced take rate.
|
10861581 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
|
10627470 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings provide evidence that IL-15 may promote tumor cell progression <i>via</i> CD215+ myeloid cells, and IGF-1 may be an important candidate that IL-15 facilitates tumor growth.
|
29255466 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo.
|
27776794 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.
|
19422685 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that compared with CAR.19(+) T cells, iC9/CAR.19/IL-15(+) T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V(+)/7-AAD(+) cells 10+/-6% for iC9/CAR.19/IL-15(+) T cells and 32+/-19% for CAR.19(+) T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1(+) cells <15% for iC9/CAR.19/IL-15(+) T cells versus >40% for CAR.19(+) T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth).
|
20428207 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2.
|
24045181 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, in vivo analysis in a lung metastasis tumor mouse model revealed a superior antitumor effect for scFv_RD_IL-15 in comparison with that obtained by an untargeted or RD missing version of IL-15 fusion protein.
|
22491823 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In xenograft models, anti-CEA-IL15 was localized in the tumor microenvironment and exhibited more potent antitumor activities than non-targeting IL-15, supporting potential application of this multifunctional fusion molecule in tumor immunotherapy.
|
30214153 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
|
19200609 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DNTs recognize tumors via innate receptors which can be up-regulated by IL-15.
|
30670085 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The demonstration that IL-15 can recover hepatic NK cell function following tumor exposure supports its inclusion in immunotherapy strategies.
|
29867983 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We utilized an IL15 superagonist to enhance the development of antigen-specific immunity initiated by the neoepitope vaccine, PD-L1 blockade to reduce tumor immunosuppression, and a tumor-targeted IL12 molecule to facilitate T-cell function within the tumor microenvironment.
|
31292145 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The human MHC class I-negative small cell lung cancer cell line, N592, genetically engineered to secrete IL-15, N592/IL-15, showed a reduced tumor growth rate, while N592 cells engineered with IL-12, N592/IL-12, grew similarly to the wild-type N592, N592 parental cells (N592pc), in nude mice.
|
12847220 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, tumor therapy based on IL-15 gene transfection was effective against Meth A tumor cells, suggesting a possible application to human neoplasms.
|
10359107 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data highlight the potential use of human dsNKG2D-IL-15 for tumor therapy.Cellular & Molecular Immunology advance online publication, 14 September 2015; doi:10.1038/cmi.2015.81.
|
26364916 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, macrophages cocultured with N592/IL-12/IL-15 produced NO in vitro, and inhibited tumor cell growth, further suggesting their role as effector cells in this model.
|
10975824 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that MeVac encoding interleukin-15 may mediate enhanced T and NK cell responses and thus increase the therapeutic efficacy, especially in NK cell-controlled tumors.
|
31623390 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Alongside expressing chimeric antigen receptors to overcome immune escape by cancer cells, enhance their recognition, and mediate their killing, NK cells have been genetically modified to enhance their persistence <i>in vivo</i> by the expression of cytokines such as IL-15, avoid functional and metabolic tumor microenvironment suppression, or improve their homing ability, enabling enhanced targeting of solid tumors.
|
30306093 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The addition of the IL-15 superagonist fusion protein complex ALT-803 enhanced the ADCC capacity of both anti-PD-L1 and M7824, and to levels that both agents now demonstrated similar levels of ADCC of tumor cells.
|
29088859 |
2017 |